[go: up one dir, main page]

ES2171547T3 - Receptor de tnf y hormona esteroidica dhea en terapia combinada. - Google Patents

Receptor de tnf y hormona esteroidica dhea en terapia combinada.

Info

Publication number
ES2171547T3
ES2171547T3 ES95926883T ES95926883T ES2171547T3 ES 2171547 T3 ES2171547 T3 ES 2171547T3 ES 95926883 T ES95926883 T ES 95926883T ES 95926883 T ES95926883 T ES 95926883T ES 2171547 T3 ES2171547 T3 ES 2171547T3
Authority
ES
Spain
Prior art keywords
dhea
steroid hormone
tnf
receptor
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95926883T
Other languages
English (en)
Inventor
Alessandra Boe
Francesco Borrelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Research Systems ARS Holding NV
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Application granted granted Critical
Publication of ES2171547T3 publication Critical patent/ES2171547T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL USO DE UN RECEPTOR DEL FNT JUNTO CON UNA HORMONA ESTEROIDEA PARA PRODUCIR UNA COMPOSICION FARMACEUTICA DESTINADA AL TRATAMIENTO DE INFECCIONES POR BACTERIAS Y VIRUS LETALES ASI COMO ENFERMEDADES AUTOINMUNITARIAS E INFLAMATORIAS. SE REFIERE TAMBIEN A DICHAS COMPOSICIONES FARMACEUTICAS PARA USO SIMULTANEO, SEPARADO O SECUENCIAL DE SUS PRINCIPIOS ACTIVOS PARA EL TRATAMIENTO ARRIBA MENCIONADO. EN PARTICULAR, SE REFIERE AL USO DE TBP - 1 JUNTO CON DESHIDROEPIANDROSTERONA (DHEA) O SUS METABOLITOS PARA PRODUCIR UNA COMPOSICION FARMACEUTICA DESTINADA AL TRATAMIENTO DEL SHOCK SEPTICO.
ES95926883T 1995-07-14 1995-07-14 Receptor de tnf y hormona esteroidica dhea en terapia combinada. Expired - Lifetime ES2171547T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1995/002767 WO1997003686A1 (en) 1995-07-14 1995-07-14 Tnf receptor and steroid hormone in a combined therapy

Publications (1)

Publication Number Publication Date
ES2171547T3 true ES2171547T3 (es) 2002-09-16

Family

ID=8166058

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95926883T Expired - Lifetime ES2171547T3 (es) 1995-07-14 1995-07-14 Receptor de tnf y hormona esteroidica dhea en terapia combinada.

Country Status (11)

Country Link
US (1) US6225300B1 (es)
EP (1) EP0839046B1 (es)
JP (1) JP4011618B2 (es)
AT (1) ATE212231T1 (es)
AU (1) AU715260B2 (es)
DE (1) DE69525181T2 (es)
DK (1) DK0839046T3 (es)
ES (1) ES2171547T3 (es)
IL (1) IL118789A0 (es)
WO (1) WO1997003686A1 (es)
ZA (1) ZA965891B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7012060B1 (en) * 1995-07-14 2006-03-14 Applied Research Systems Ars Holding N.V. TNF receptor and steroid hormone in a combined therapy
NL1006876C2 (nl) 1997-08-28 1999-03-02 Schiphol Luchthaven Nv Platform voor het parkeren en afhandelen van vliegtuigen.
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20050002900A1 (en) * 2001-11-06 2005-01-06 Grace Wong Method of treating estrogen responsive breast cancer
SI1471974T1 (sl) * 2002-02-06 2007-12-31 Ares Trading Sa Tumorje nekrotizirajoäśi faktor, kombiniran z interferonom, pri demielinizirajoäśih boleznih
ES2304602T3 (es) 2003-02-28 2008-10-16 Ares Trading S.A. Formulaciones liquidas de la proteina de union al factor de necrosis tumoral tbp-1.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
SG63617A1 (en) * 1991-01-18 1999-03-30 Amgen Boulder Inc Methods for treating tumar necrosis factor mediated diseases
JPH07504203A (ja) 1992-09-15 1995-05-11 イミュネックス・コーポレーション 腫瘍壊死因子アンタゴニストを用いるｔｎｆ−依存性炎症の治療方法
EP1004312A1 (en) 1993-07-30 2000-05-31 Kennedy Institute Of Rheumatology Method for treating multiple sclerosis

Also Published As

Publication number Publication date
AU3110995A (en) 1997-02-18
US6225300B1 (en) 2001-05-01
IL118789A0 (en) 1996-10-31
JP4011618B2 (ja) 2007-11-21
HK1009403A1 (en) 1999-06-04
DK0839046T3 (da) 2002-02-18
DE69525181D1 (de) 2002-03-14
ATE212231T1 (de) 2002-02-15
DE69525181T2 (de) 2002-08-14
AU715260B2 (en) 2000-01-20
ZA965891B (en) 1997-03-19
EP0839046A1 (en) 1998-05-06
JPH11509213A (ja) 1999-08-17
EP0839046B1 (en) 2002-01-23
WO1997003686A1 (en) 1997-02-06

Similar Documents

Publication Publication Date Title
EA200201000A1 (ru) Гормон-заместительная терапия
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
MD1920F2 (ro) Compoziţie şi metodă de profilaxie sau frânare a debutului bolii Alzheimer
YU69000A (sh) Antitela za cd23, njihovi derivati i njihove terapeutske upotrebe
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
EA200600964A1 (ru) Фармацевтический препарат для непрерывного гормонального лечения в течение периода времени более длительного, чем 21-28 дней, включающий две композиции эстрогена и/или прогестина
FR14C0051I2 (fr) Dialkylfumarates pour le traitement de maladies autoimmunes
HRP20020787B1 (hr) Postupak liječenja upotrebom kompleksa ligand-imunogen
ATE217192T1 (de) Kombinationsprodukt zur kontrazeption enthaltend progesteronantagonisten und gestagenen
MY131522A (en) PHARMACEUTICAL COMPOSITION AND USES FOR ANDROST-5-ENE-3ß,17ß-DIOL
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
TR199802705T2 (xx) Progestojen-anti-progestojen k�r�
AU2740797A (en) Androstene derivatives
DK1392329T3 (da) Anvendelse af sulodexid til behandling af inflammatorisk tarmsygdom
WO2006053172A3 (en) The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases
BR9710566A (pt) M-todo anticoncepcional monof sico e um kit compreendendo uma combina-Æo de uma progestina e estrog-nio
AU2732597A (en) Novel pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
CA2504697A1 (en) Methods for treating migraine
EP0663835A1 (en) USE OF PARATHORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES FOR THE TREATMENT OF PREGNANCY PROBLEMS.
ES2171547T3 (es) Receptor de tnf y hormona esteroidica dhea en terapia combinada.
AU9363398A (en) Hepatitis c receptor protein cd81
BR0008076A (pt) 16-hidroxiestratrienos como estrogênios de efeito seletivo
KR960030947A (ko) src SH2 특이성 화합물의 골흡수 질환 치료 용도
BG103060A (en) 19-nor-holan steroids as neurochemical initiators of the change of the operation of the hypothalamus in human organism
PT921804E (pt) Metodo contraceptivo bifasico e conjunto ("kit") compreendendo uma combinacao de uma progestina e um estrogenio

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 839046

Country of ref document: ES